靶向头颈癌肿瘤相关抗原的免疫治疗小鼠模型研究
研究通过计算机算法预测小鼠c-Met来源的新型T细胞表位,并用c-Met肽疫苗治疗小鼠头颈鳞癌(HNSCC)细胞系荷瘤小鼠。疫苗通过CD8和/或CD4 T细胞诱导显著抗肿瘤反应,无需免疫检查点抑制剂(ICIs),且接种小鼠排斥再接种的肿瘤。结论提示c-Met肽疫苗可诱导抗肿瘤T细胞反应,可能成为同基因小鼠HNSCC模型的有效免疫治疗。
要点
- 计算机算法预测出c-Met来源的短肽和长肽表位,可激发c-Met反应性抗肿瘤CD8和/或CD4 T细胞反应。
- 使用这些肽段接种疫苗通过T细胞显示出显著抗肿瘤反应,且不需要ICIs。
- c-Met肽疫苗接种的小鼠排斥再接种的肿瘤。
核心结论
- 新型c-Met肽疫苗可诱导抗肿瘤T细胞反应,在同基因小鼠HNSCC模型中可能是一种有效的免疫治疗。
研究设计与样本
- 研究为小鼠头颈鳞癌(HNSCC)细胞系荷瘤小鼠模型,采用计算机算法预测c-Met来源T细胞表位,并用c-Met肽疫苗治疗,评估CD8和/或CD4 T细胞清除及疫苗联合免疫检查点抑制剂(ICIs)的效果,并进行肿瘤再接种评估T细胞记忆。
主要发现
- 鉴定出c-Met来源的短肽和长肽表位,可激发c-Met反应性抗肿瘤CD8和/或CD4 T细胞反应。
- 使用这些肽段接种疫苗通过T细胞显示出显著抗肿瘤反应,且不需要ICIs。
- c-Met肽疫苗接种的小鼠排斥再接种的肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The identification of epitope peptides from tumor-associated antigens (TAAs) is informative for developing tumor-specific immunotherapy. However, only a few epitopes have been detected in mouse TAAs of head and neck cancer (HNSCC). METHODS: Novel mouse c-Met-derived T-cell epitopes were predicted by computer-based algorithms. Mouse HNSCC cell line-bearing mice were treated with a c-Met peptide vaccine. The effects of CD8 and/or CD4 T-cell depletion, and vaccine combination with immune checkpoint inhibitors (ICIs) were evaluated. Tumor re-inoculation was performed to assess T-cell memory. RESULTS: We identified c-Met-derived short and long epitopes that elicited c-Met-reactive antitumor CD8 and/or CD4 T-cell responses. Vaccination using these peptides showed remarkable antitumor responses via T cells in which ICIs were not required. The c-Met peptide-vaccinated mice rejected the re-inoculated tumors. CONCLUSIONS: We demonstrated that novel c-Met peptide vaccines can induce antitumor T-cell response, and could be a potent immunotherapy in a syngeneic mouse HNSCC model.
引用
- Kono M, Wakisaka R, Komatsuda H, et al. Immunotherapy targeting tumor-associated antigen in a mouse model of head and neck cancer. Head Neck. 2024. PMID: 38390628. doi:10.1002/hed.27703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。